Rallybio Corporation
RLYBNASDAQHealthcare● Active
$16.22
+$0.31(+1.95%)
Market Cap$85935831
P/E Ratio—
52W High$17.574
52W Low$2.4
Rallybio Corporation (RLYB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RLYB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$1.46
Est. -$1.20 · -21.7%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
RLYB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.28 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$1.20 | -$1.46 | -21.7% | $0.00B | $0.00B | +0.0% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$1.24 | -$1.11 | +10.5% | $0.00B | $0.00B | +122.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.25 | -$0.14 | +44.0% | $0.00B | $0.00B | +218.0% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.20 | -$0.22 | -12.8% | $0.00B | $0.00B | +218.0% |
| — Q2 FY2025 | May 8, 2025 | -$0.21 | -$0.21 | +0.0% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.27 | -$0.25 | +7.4% | $0.00B | $0.00B | -74.6% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.36 | -$0.26 | +27.8% | $0.00B | $0.00B | +298.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$1.46
EPS Est.
-$1.20
EPS Surpr.
-21.7%
Revenue
$0.00B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$1.11
EPS Est.
-$1.24
EPS Surpr.
+10.5%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$0.25
EPS Surpr.
+44.0%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.22
EPS Est.
-$0.20
EPS Surpr.
-12.8%
Revenue
$0.00B
Q2 FY2025
May 8, 2025
EPS Actual
-$0.21
EPS Est.
-$0.21
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.27
EPS Surpr.
+7.4%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.26
EPS Est.
-$0.36
EPS Surpr.
+27.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.60 | $-1.60 | $-1.60 | 1 |
| Q3 FY2026 | $-1.44 | $-1.44 | $-1.44 | 1 |
| Q2 FY2026 | $-1.28 | $-1.28 | $-1.28 | 1 |
| Q1 FY2026 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q4 FY2025 | $-1.24 | $-1.24 | $-1.24 | 1 |
| Q3 FY2025 | $-1.71 | $-1.71 | $-1.71 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -21.7% | $14.03 | $14.35 | +2.28% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +10.5% | $9.98 | $9.60 | -3.81% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +44.0% | $5.00 | $5.11 | +2.20% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -12.8% | $4.22 | $4.09 | -3.08% |
| ▲ Q2 FY2025 | May 8, 2025 | +0.0% | $2.40 | $2.34 | -2.50% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +7.4% | $5.27 | $5.25 | -0.38% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +27.8% | $8.00 | $7.92 | -1.00% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +11.9% | $9.60 | $9.52 | -0.83% |
Q2 FY2026+2.28%
Report Date
May 13, 2026
EPS Beat/Miss
-21.7%
Price Before
$14.03
Price After
$14.35
Q1 FY2026-3.81%
Report Date
Mar 12, 2026
EPS Beat/Miss
+10.5%
Price Before
$9.98
Price After
$9.60
Q4 FY2025+2.20%
Report Date
Nov 6, 2025
EPS Beat/Miss
+44.0%
Price Before
$5.00
Price After
$5.11
Q3 FY2025-3.08%
Report Date
Aug 7, 2025
EPS Beat/Miss
-12.8%
Price Before
$4.22
Price After
$4.09
Q2 FY2025-2.50%
Report Date
May 8, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.40
Price After
$2.34
Q1 FY2025-0.38%
Report Date
Mar 13, 2025
EPS Beat/Miss
+7.4%
Price Before
$5.27
Price After
$5.25
Q4 FY2024-1.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
+27.8%
Price Before
$8.00
Price After
$7.92
Q3 FY2024-0.83%
Report Date
Aug 8, 2024
EPS Beat/Miss
+11.9%
Price Before
$9.60
Price After
$9.52
Avg Beat Reaction-1.05%
Avg Miss Reaction-0.40%
Beat Rate6 / 8 quarters
Largest Move-3.81% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RLYB ends December
Rallybio Corporation (RLYB) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-1.46 — missing the analyst consensus of $-1.20 by -21.7%. The next RLYB earnings date is expected around September 1, 2026.
Each quarter, investors track RLYB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RLYB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RLYB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RLYB earnings · 5 questionsRallybio Corporation's next earnings report is expected around September 1, 2026. RLYB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RLYB historically reports after market close (AMC).
RLYB earnings datewhen is RLYB earningsRLYB next earnings datewhen does RLYB report earningsRLYB earnings calendar
▸ Source: FMP · Rallybio Corporation SEC filings · US GAAP · Rallybio Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026